Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis

NCT07545213 is registered in ClinicalTrials.gov with The Fourth Affiliated Hospital of Zhejiang University School of Medicine as lead sponsor.

NCT NCT07545213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07545213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis
Lead sponsor
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 20, 2026
Completion date
August 15, 2028
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr mutant advanced non-small cell lung cancer, non-small cell lung cancer